Unicycive Therapeutics (UNCY) Research & Development (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Research & Development came in at $1.6 million in Q1 2026, down 25.98% YoY from $2.2 million in Q1 2025, and down 28.58% on a QoQ basis from $2.2 million in Q4 2025.
Unicycive Therapeutics (UNCY) Research & Development (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Research & Development data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Research & Development fell 25.98% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (down 44.24% YoY) and the FY2025 annual result came in at $9.1 million, down 54.43% from the prior year.
- Research & Development fell to $1.6 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $12.1 million in Q4 2022 to a low of $103000.0 in Q3 2022.
- A 5-year average of $3.5 million and a median of $3.0 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development soared 3173.79% — and 2025, when it tumbled 68.13%.
- Tracing UNCY's Research & Development over 5 years: stood at $12.1 million in 2022, then slumped by 65.11% to $4.2 million in 2023, then climbed by 24.92% to $5.3 million in 2024, then sank by 57.45% to $2.2 million in 2025, then fell by 28.58% to $1.6 million in 2026.
- The last three Research & Development figures came in at $1.6 million (Q1 2026), $2.2 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.79 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 2.96 Mn |
| Jun 30, 2025 | 1.75 Mn |
| Mar 31, 2025 | 2.17 Mn |
| Dec 31, 2024 | 5.29 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 4.87 Mn |
| Mar 31, 2024 | 6.81 Mn |
| Dec 31, 2023 | 4.23 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 2.27 Mn |
| Mar 31, 2023 | 3.03 Mn |
| Dec 31, 2022 | 12.13 Mn |
| Sep 30, 2022 | 103,000.00 |
| Jun 30, 2022 | 1.86 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | -1.48 Mn |
| Sep 30, 2021 | 167,000.00 |